XML 16 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Revenues        
Research and development $ 4,264,561 $ 1,901,314 $ 9,466,347 $ 3,171,047
Operating expenses        
Selling, general and administrative 3,058,244 3,738,709 5,928,113 6,394,940
Research and development 5,067,838 2,948,391 11,428,327 5,484,403
Patent expenses 197,017 239,690 437,615 459,405
Interest on PharmAthene liability 0 4,259,451 0 7,176,637
Total operating expenses 8,323,099 11,186,241 17,794,055 19,515,385
Operating loss (4,058,538) (9,284,927) (8,327,708) (16,344,338)
Gain (loss) from change in fair value of warrant liability 294,356 0 (331,853) 0
Interest expense (3,652,496) (10,214) (7,261,412) (10,214)
Other income, net 8,066 58,489 12,484 69,800
Reorganization items, net 0 (327,729) 0 (3,716,902)
Loss before income taxes (7,408,612) (9,564,381) (15,908,489) (20,001,654)
Provision for income taxes (92,825) (1,470) (207,895) (12,764)
Net and comprehensive loss $ (7,501,437) $ (9,565,851) $ (16,116,384) $ (20,014,418)
Loss per share: basic and diluted $ (0.10) $ (0.18) $ (0.20) $ (0.37)
Weighted average shares outstanding: basic and diluted 78,840,312 54,216,604 78,808,903 54,165,450